# NIAID- VRC HIV mAb-Research, Development, and Production to Support HIV Monoclonal Antibody Development

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $13,145,256

## Abstract

The NIAID mission and scope includes rapidly responding to infectious disease outbreaks through research, development, and testing of HIV vaccines and therapeutics

## Key facts

- **NIH application ID:** 10722410
- **Project number:** 75N91019D00024-P00001-759102200001-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** DAVID LINDSAY
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $13,145,256
- **Award type:** —
- **Project period:** 2022-02-01 → 2027-08-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10722410

## Citation

> US National Institutes of Health, RePORTER application 10722410, NIAID- VRC HIV mAb-Research, Development, and Production to Support HIV Monoclonal Antibody Development (75N91019D00024-P00001-759102200001-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10722410. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*